| HOME >> BIOLOGY >> TECHNOLOGY |
About Northern Antibiotics Ltd.
Founded in 2003 and headquartered in Helsinki, Finland, Northern
Antibiotics Ltd. is engaged in the discovery and development of novel
antibiotics against multidrug-resistant Gram-negative bacteria. The NAB
compounds are polymyxin derivatives that have less cationic charges than
the polymyxins currently in clinical use. This difference is believed to
result in reduced nephrotoxicity of the novel compounds. For more
information, visit http://www.northernantibiotics.com.
Contact:
Dr. Barry Mason
Business Development Consultant
Email: barry.mason@northernantibiotics.com
Phone: +44(0)1625-858396
Mobile: +44(0)7713-261356
| SOURCE Northern Antibiotics Ltd Copyright©2008 PR Newswire. All rights reserved |